Clinical Trials Logo

Positron-Emission Tomography clinical trials

View clinical trials related to Positron-Emission Tomography.

Filter by:

NCT ID: NCT04831034 Recruiting - Fibrosis Clinical Trials

68Ga-FAPI PET/CT in Patients With Various Fibrotic Disease

Start date: April 1, 2021
Phase: Early Phase 1
Study type: Interventional

To evaluate the potential value of 68Ga-FAPI-04 positron emission tomography/ computed tomography (PET/CT) for the diagnosis and prognosis in fibrotic disease

NCT ID: NCT04750772 Recruiting - Colorectal Cancer Clinical Trials

Positron Nuclide Labeled DOTA-FAPI PET Study in Colocrectal Cancer

Start date: October 16, 2019
Phase: N/A
Study type: Interventional

To evaluate the normal physiological distribution of positron nuclide labeled DOTA-FAPI PET/CT in human body and its diagnostic efficiency for colorectal cancers

NCT ID: NCT04605939 Recruiting - Clinical trials for Magnetic Resonance Imaging

Clinical Application of Fibroblast Activation Protein PET/MRI in Liver Fibrosis

Start date: July 1, 2020
Phase: N/A
Study type: Interventional

Positron Emission Tomography (PET) provides a valuable tool for the diagnosis and staging of liver fibrosis. Activation of hepatic stellate cell (HSC) is a key link in the pathophysiological development of liver fibrosis. In human liver tissue, fibroblast activation protein (FAP) was only expressed in active HSCs and fibroblasts, but not in static HSCs. Therefore, FAP has become an excellent target for diagnosis and treatment of liver fibrosis. Recently, radionuclide-labeled fibroblast activation protein inhibitors (FAPI) as a new novel positron tracer has shown to be effective to detect various cancers. In this prospective study, the investigators will use the most advanced imaging equipments, integrated PET/MR, and PET/CT with gallium-68 (68Ga) -FAPI to image patients with or suspected of liver fibrosis, the aim is to explore the value of 68Ga-FAPI hybrid PET/MR and PET/CT in liver fibrosis.

NCT ID: NCT04555642 Recruiting - Clinical trials for Magnetic Resonance Imaging

Early Diagnosis of Therapy-associated Cardiotoxicity Basing on Multi-tracer Multimodality PET/MRI

Start date: September 15, 2020
Phase:
Study type: Observational

Using Multi-tracer to early diagnosis of therapy-associated cardiotoxicity using multimodality PET/MRI.

NCT ID: NCT04533828 Recruiting - Liver Fibrosis Clinical Trials

68Ga-FAPI PET/CT in Liver Fibrosis Patients

GFAPILF
Start date: September 1, 2020
Phase: Early Phase 1
Study type: Interventional

To evaluate the potential value of 68Ga-FAPI-04 positron emission tomography/computed tomography (PET/CT) for the diagnosis and prognosis in liver fibrosis disease.

NCT ID: NCT04525612 Recruiting - Tumor Clinical Trials

68Ga-BNU-PSMA PET/CT in Patients With Various Types of Cancer

Start date: August 21, 2020
Phase: Early Phase 1
Study type: Interventional

To evaluate the potential usefulness of 68Ga-BNU-PSMA positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various types of cancer.

NCT ID: NCT04514822 Recruiting - Clinical trials for Esophageal Squamous Cell Carcinoma

Quantitative Evaluation of Metastatic Lymph Nodes With Dynamic 18F-FDG PET/CT in Patients With ESCC

Start date: March 1, 2019
Phase: N/A
Study type: Interventional

Currently, static scans are commonly used for Positron Emission Tomography/Computed Tomography (PET/CT) examination in the literature. Accordingly, functional images of 2-[18F]fluoro-2-deoxy-glucose (18F-FDG) Positron Emission Tomography/Computed Tomography (PET/CT) with dynamic scans can be more sensitive to detect metastatic lymph node, since the introduction of temporal dynamic variables would provide more imaging quantification than conventional static scans. The purpose of this study is to provide the dynamic 18F-FDG PET/CT imaging for esophageal squamous cell carcinoma (ESCC) patient to quantify the difference between malignant lymph nodes (MLN) and benign lymph nodes (BLN).

NCT ID: NCT04499365 Recruiting - Tumor Clinical Trials

68Ga-FAPI PET/CT in Patients With Various Types of Cancer

Start date: August 15, 2020
Phase: Early Phase 1
Study type: Interventional

To evaluate the potential usefulness of 68Ga-DOTA/NOTA-FAPI-04 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various types of cancer.

NCT ID: NCT04416165 Recruiting - Metastasis Clinical Trials

Comparison of FDG and FAPI in Patients With Various Types of Cancer

Start date: October 20, 2019
Phase: N/A
Study type: Interventional

To evaluate the potential usefulness of 68Ga-DOTA-FAPI-04 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various types of cancer, compared with 18F-FDG PET/CT.

NCT ID: NCT03830242 Recruiting - Thyroid Cancer Clinical Trials

Diagnostic Significance of FDG PET/CT Dynamic Imaging in Detecting Metastatic Lymph Nodes With Papillary Thyroid Cancer.

Start date: November 1, 2018
Phase: N/A
Study type: Interventional

The aim of this study is to make up for the gap by performing a dynamic scan of <Sup>18<Sup>F-FDG PET/CT on newly diagnosed patients with papillary thyroid carcinoma. Pathological and genomic studies are performed. The differences between metastatic central lymph nodes images and tissues are compared at the same time. <Sup>18<Sup>F-FDG PET/CT dynamic imaging is explored in metastatic central lymph nodes with papillary thyroid cancer for the diagnostic value.